We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Assessment of Tau Protein Status for Early Detection of Alzheimer's Disease

By LabMedica International staff writers
Posted on 03 Jan 2017
Print article
Image: High molecular weight tau bands (about 80kDa) can be visualized, with greater immunoreactivity, in patients with AD compared with healthy subjects (Photo courtesy of Dr. Ricardo B. Maccioni, University of Chile).
Image: High molecular weight tau bands (about 80kDa) can be visualized, with greater immunoreactivity, in patients with AD compared with healthy subjects (Photo courtesy of Dr. Ricardo B. Maccioni, University of Chile).
The ratio of normal to aggregated tau protein found in blood platelets has been suggested as a biomarker that could be used for the early detection of Alzheimer's disease.

Investigators at the University of Chile (Santiago, Chile) previously had established the methodology that enables detection of the pathological oligomeric forms of brain tau protein in human blood platelets in patients with Alzheimer's disease (AD) and other neurodegenerative disorders.

The current study cited the use of this methodology to determine whether high molecular weight (HMW) or low molecular weight (LMW) tau protein levels, as well as the ratio HMW/LMW, present in platelets correlated with brain magnetic resonance imaging (MRI) structural changes in normal and cognitively impaired subjects. The investigators examined 53 AD patients and 37 cognitively normal subjects recruited from two memory clinics at the University of Chile. Tau levels in platelets were determined by immunoreactivity and corresponding MRI scans were analyzed.

Results published in the December 20, 2016, issue of the Journal of Alzheimer's Disease revealed that the HMW/LMW tau ratio was statistically different between controls and AD patients, and no associations were noted between HMW or LMW tau and MRI structures. The HMW/LMW tau ratio was associated with reduced volume in the left medial and right anterior cingulate gyri, right cerebellum, right thalamus (pulvinar), left frontal cortex, and right parahippocampal region.

The investigators concluded that this exploratory study showed that the HMW/LMW tau ratio was significantly higher in AD patients than control subjects, and that it was associated with the atrophy of specific regions in the brain. Determination of peripheral markers of AD pathology could help in understanding the pathophysiology of neurodegeneration in AD.

Related Links:
University of Chile

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more